The U.S. Market for Intranasal Drug Delivery is Projected to Exceed US$8.1 Billion by 2024

The Continued Quest for Non-Invasive Drug Delivery Systems Spurs Encouraging Advancements in Intranasal Drug Delivery, According to a New Report by Global Industry Analysts, Inc.

                                                                                                

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size, and demand forecasts on the Intranasal Drug Delivery market. The U.S. market for Intranasal Drug Delivery is projected to exceed US$8.1 billion by 2024, driven by the quest to develop an efficient and non-invasive route for systemic drug administration, as well as efforts to increase bioavailability.

                                                                                             

Intranasal drug delivery, a highly effective method involving the administration of drugs through the nasal cavity, is gaining prominence for its effectiveness in the treatment of a growing range of chronic and acute conditions, including allergic infections, analgesics, osteoporosis to pain management, anxiety, depression, and sexual dysfunction. Researchers and drug developers are developing novel drug delivery technologies that enhance patient outcomes by offering greater therapeutic benefits and by encouraging higher patient compliance. A growing range of local anesthetics, antibiotics, antihistamines, bronchodilators, calcium, corticosteroids, decongestant sprays, pain relief drugs, snuffs, supplements, vasoconstrictors and other drugs are administered through the intranasal route in the form of ointments, sprays, powders, gels, and drops. Increasing R&D is unlocking more therapeutic areas for nasal drug delivery, including pain, Attention Deficit Hyperactivity Disorder (ADHD), opioid overdose, Gastroparesis, migraine, and Social Anxiety Disorder (SAD).

The primary factor driving growth in the market is the growing incidence of diseases such as allergic rhinitis and neurological disorders like Alzheimer’s disease and depression. The popularity and universal acceptance of intranasal drug administration by doctors and researchers alike is largely due to the technique’s efficiency and ease in delivering systemic drugs. The rapidly aging population is lending momentum to the development of intranasal drugs and drug-delivery devices that are minimally invasive and disruptive to the quality of life of patients. Intranasal Drug Delivery offers opportunities for new target areas to improve bioavailability of drugs. Scientists and researchers are realizing up to the benefits and numerous advantages of utilizing the nose as a route for escorting drugs to the target disease site. The unique vascular structure of the nose makes this organ especially accessible for delivery of small molecule drugs and biologics.

The Blood Brain Barrier (BBB) is one of the target areas for intranasal drug delivery. Tight junctions of endothelial cells of capillaries carrying blood to the brain form a barrier against majority of the drugs, restricting the drugs’ and solutes’ ability to transit through the BBB. The barrier effectively limits the amount of hydrophilic compounds flowing to brain tissues from the vascular compartment. There is increasing scientific evidence to suggest that drug delivery through the nasal route is likely to lead to higher drug concentrations passing through the BBB. The nose offers one of the most direct routes to the brain and this factor is being extensively being researched to breach the Blood Brain Barrier to increase bioavailability of drugs, as the nose as a compatible drug delivery route helps drug molecules to effectively cross the body’s biological sentinels to reach the Central Nervous System.

As stated by the new market research report on Intranasal Drug Delivery, Allergic Infections represent the largest therapeutic area, and constitute the bulk of drugs delivered through the intranasal route in the United States. Osteoporosis Drugs and Analgesics represent the other major therapeutic areas for intranasal drug delivery with Analgesics representing the fastest growing segment with a CAGR of 13% over the analysis period.

Major players in the market include Aegis Therapeutics LLC, AptarGroup Inc., AstraZeneca Plc, MedImmune Inc., Becton Dickinson and Company, GlaxoSmithKline Plc, Johnson & Johnson Inc., Marina Biotech Inc., Merck & Co. Inc., Nemera, Novartis AG, OptiNose US Inc., Pfizer Inc., and Valeant Pharmaceuticals International Inc. among others.

The research report titled "Intranasal Drug Delivery: A US Market Report" announced by Global Industry Analysts Inc., analyzes a wealth of data including technological trends, growth drivers and major challenges that are shaping the US Intranasal Drug Delivery market, as well as profiles of leading vendors, mergers, acquisitions and other strategic industry activities. The report provides market estimates and projections for the US market for Intranasal Drug Delivery Therapeutics for Allergic Infections, Analgesics, Osteoporosis, and Vaccination therapeutic areas.

For enquiries e-mail us at rsd@strategyr.com or info411@strategyr.com.

To connect with us, visit our LinkedIn page.

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.